About: De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate
Creator	Alepopoulou, Eleonora Alepopoulou, · Efraimidou, Eleni Efraimidou, · Giantsou, Elpis Giantsou, E Kartali-Ktenidou, Sofia Kartali-Ktenidou, · Liratzopoulos, Nikolaos Liratzopoulos, · Manolas, Konstantinos Manolas, · Panopoulou, Maria Panopoulou, M
Source	PMC
abstract	OBJECTIVE: To assess outcomes with de-escalation therapy in ventilator-associated pneumonia (VAP). DESIGN: Prospective observational study. SETTING: Multidisciplinary intensive care unit. PATIENTS AND PARTICIPANTS: VAP was diagnosed by positive quantitative cultures of both tracheal aspirate and bronchoalveolar lavage (BAL) and treated appropriately for all significant isolates of tracheal aspirate and BAL in 143 patients who were assigned to de-escalation therapy by BAL or tracheal aspirate. INTERVENTIONS: None. MEASUREMENTS AND RESULTS: Antibiotic therapy was de-escalated in 58 patients (40.5%), who had decreased mortality at day 15 (5.1% vs. 31.7%) and day 28 (12% vs. 43.5%) and shorter intensive care unit (17.2 ± 1.2 vs. 22.7 ± 6.3 days) and hospital (23.7 ± 2.8 vs. 29.8 ± 11.1 days) stay (p < 0.05). Of the 81 patients assigned to tracheal aspirate, the 17 (21%) who achieved de-escalation of therapy had reduced 15-day mortality (5.8% vs. 34.3%), reduced 28-day mortality (11.6% vs. 45.3%), and shorter intensive care unit (17.2 ± 1.6 vs. 22.4 ± 6.4 days) and hospital (23.1 ± 4.4 vs. 29.9 ± 11.1 days) stay (p < 0.05). Of the 62 patients assigned to BAL, the 41 (66.1%) who achieved de-escalation of therapy had decreased 15-day mortality (4.8% vs. 23.8%), decreased 28-day mortality (12.1% vs. 38%), and shorter intensive care unit (17.2 ± 1.1 vs. 23.2 ± 6 days) and hospital (23.8 ± 2.4 vs. 29.8 ± 11.4 days) stay (p < 0.05). CONCLUSIONS: For patients with VAP who have had appropriate treatment and shown a favorable clinical response, mortality and duration of stay can be further improved by de-escalation therapy.
has issue date	2007-06-05(xsd:dateTime)
bibo:doi	10.1007/s00134-007-0619-x
bibo:pmid	17549458
has license	no-cc
sha1sum (hex)	b8015e392a4d9b0e5f940aee0abe42b357a8ea3c
schema:url	https://doi.org/10.1007/s00134-007-0619-x
resource representing a document's title	De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate
has PubMed Central identifier	PMC7095354
has PubMed identifier	17549458
schema:publication	Intensive Care Med
resource representing a document's body	covid:b8015e392a4d9b0e5f940aee0abe42b357a8ea3c#body_text
is schema:about of	named entity 'mortality' named entity 'days' named entity 'day' named entity 'intensive care unit' named entity 'aspirate' named entity 'DECREASED' named entity 'OUTCOMES' named entity 'CONCLUSIONS' named entity '0.05' named entity 'IMPROVED BY' named entity 'MULTIDISCIPLINARY' named entity 'ESCALATION' covid:arg/b8015e392a4d9b0e5f940aee0abe42b357a8ea3c named entity 'days' named entity 'mortality' named entity 'mortality' named entity 'aspirate' named entity 'patients' named entity 'duration' named entity 'mortality' named entity 'de-escalation' named entity 'Interventions' named entity 'shorter' named entity 'hospital' named entity 'de-escalation' named entity 'intensive care unit' named entity 'bronchoalveolar lavage' named entity 'de-escalation' named entity 'de-escalation' named entity 'aspirate' named entity 'P. aeruginosa' named entity 'infection' named entity 'tracheal' named entity 'P. aeruginosa' named entity 'de-escalation' named entity 'de-escalation' named entity 'pathogens' named entity 'bacteriology' named entity 'Gram-negative bacteria' named entity 'antibiotics' named entity 'p-values' named entity 'intensive care unit' named entity 'De-escalation' named entity 'de-escalation' named entity 'clinical diagnosis' named entity 'VAP' named entity 'antibiotic therapy' named entity 'de-escalation' named entity 'de-escalation' named entity 'antibiotic therapy' named entity 'combination regimen' named entity 'extended-spectrum penicillin' named entity 'tracheal' named entity 'Antibiotics' named entity 'P. aeruginosa' named entity 'de-escalation' named entity 'piperacillin/tazobactam' named entity 'Serratia marcescens' named entity 'VAP' named entity 'aminoglycoside' named entity 'ICU' named entity 'empiric antibiotic' named entity 'ICU' named entity 'P. aeruginosa' named entity 'De-escalation' named entity '7.1' named entity 'de-escalation' named entity 'P. aeruginosa'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software